Correlation Between Mineralys Therapeutics, and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Cue Biopharma, you can compare the effects of market volatilities on Mineralys Therapeutics, and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Cue Biopharma.
Diversification Opportunities for Mineralys Therapeutics, and Cue Biopharma
0.82 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Mineralys and Cue is 0.82. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Cue Biopharma go up and down completely randomly.
Pair Corralation between Mineralys Therapeutics, and Cue Biopharma
Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.74 times more return on investment than Cue Biopharma. However, Mineralys Therapeutics, Common is 1.36 times less risky than Cue Biopharma. It trades about -0.06 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.26 per unit of risk. If you would invest 1,389 in Mineralys Therapeutics, Common on August 29, 2024 and sell it today you would lose (137.00) from holding Mineralys Therapeutics, Common or give up 9.86% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Mineralys Therapeutics, Common vs. Cue Biopharma
Performance |
| Timeline |
| Mineralys Therapeutics, |
| Cue Biopharma |
Mineralys Therapeutics, and Cue Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Mineralys Therapeutics, and Cue Biopharma
The main advantage of trading using opposite Mineralys Therapeutics, and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.| Mineralys Therapeutics, vs. Eliem Therapeutics | Mineralys Therapeutics, vs. Scpharmaceuticals | Mineralys Therapeutics, vs. Milestone Pharmaceuticals | Mineralys Therapeutics, vs. Seres Therapeutics |
| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |